|4Feb 2, 5:00 PM ET

Chipman Christopher Michael 4

4 · Virpax Pharmaceuticals, Inc. · Filed Feb 2, 2022

Insider Transaction Report

Form 4
Period: 2022-01-31
Chipman Christopher Michael
Chief Financial Officer
Transactions
  • Award

    Stock Option (right to buy)

    2022-01-31+100,000100,000 total
    Exercise: $2.13Exp: 2032-01-31Common Stock (100,000 underlying)
Footnotes (1)
  • [F1]The option vests in three equal annual installments commencing on January 31, 2023.

Documents

1 file
  • 4
    virpax_fm4jan312022.xmlPrimary